Partner Headlines - CPHD

  1. Stocks Lower In Late Trading, But Utilities Rally

    IBD
  2. Craig-Hallum Upgrades Cepheid To Buy

    Benzinga
  3. Morning Market Gainers

    Benzinga
  4. US Stock Futures Rise Ahead Of Earnings, Economic Data

    Benzinga
  5. Novartis, Verastem & Cepheid Making Biotech Headlines On Friday

    Benzinga
  6. Leading Medical Stock Cepheid Trying To Break Out

    IBD
  7. Benzinga's Top Upgrades

    Benzinga
  8. Bank of America Upgrades Cepheid To Buy

    Benzinga
  9. UPDATE: Citigroup Reiterates On Cepheid Following Positive Data

    Benzinga
  10. Top Medical Stocks: Cepheid Diagnostics Sales Strong

    IBD
  11. Cepheid Receives FDA Clearance For Xpert Norovirus, The First ...

    Benzinga
  12. CEPHEID

    IBD
  13. Cepheid Receives FDA Clearance For Xpert Flu/RSV XC

    Benzinga
  14. Cepheid To Develop Xpert Ebola For Countries Worst Hit By Epidemic

    Benzinga
  15. Several Sectors Emerge As Leaders Of New Market Uptrend

    IBD
  16. Stocks Fight Back To Finish Mixed

    IBD
  17. Dow, Nasdaq Battle Near Flat Line; Energy Weighs On S&P 500

    IBD
  18. Cepheid Explores Test For Ebola Disease; Q3 Beats

    IBD
  19. CEPHEID

    IBD
  20. Cepheid Extends Reach Of Direct US Commercial Operations

    Benzinga
  21. UPDATE: ISI Group Upgrades Cepheid

    Benzinga
  22. CEPHEID

    IBD
  23. LinkedIn, TripAdvisor, Google: Top Manager's Ideas

    IBD
  24. Alexion Takes Off On Outlook

    IBD
  25. Three Medical Tech Names To Watch In Healthcare Space

    IBD
  26. Align Leads Three Top-Rated Medical Equipment Stocks

    IBD
  27. UPDATE: JMP Securities Initiates Coverage on Cepheid on Market ...

    Benzinga
  28. Five Medical Stocks Leaders Trade Near New Highs

    IBD
  29. ViroPharma Gets Bought Out; Medicines Clears Entry

    IBD
  30. UPDATE: ISI Group Downgrades Cepheid on Key Drivers Constraining ...

    Benzinga
  31. Benzinga's Top Downgrades

    Benzinga
  32. UPDATE: Bank of America Downgrades Cepheid on Fair Valuation

    Benzinga
  33. Benzinga's Top Downgrades

    Benzinga
  34. Cepheid Reports Xpert MTB/RIF Categorized 'Moderate Complexity' ...

    Benzinga
  35. Cepheid Announces Board of Directors Changes

    Benzinga
  36. Cepheid's Chlamydia and N. Gonorrhoeae Test Categorized 'Moderate ...

    Benzinga
  37. Medtech Stocks Moving As Conference Makes Waves

    IBD
  38. Medtech Stocks Moving As Conference Makes Waves

    IBD
  39. Cepheid Offers Update on Xpert Test Availability, Sees Q4 Sales ...

    Benzinga
  40. UPDATE: Piper Jaffray Downgrades Cepheid to Neutral, Lowers PT

    Benzinga
  41. Oppenheimer Holdings Reiterates Outperform Rating, $43 PT on ...

    Benzinga
  42. Canaccord Genuity Reiterates Buy Rating, $50 PT on Cepheid

    Benzinga
  43. Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid

    Benzinga
  44. US Stock Futures Down Ahead Of Economic Data

    Benzinga
  45. Stocks To Watch For December 28, 2012

    Benzinga
  46. UPDATE: Cepheid Wins FDA Clearance for Xpert CT/NG

    Benzinga
  47. UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, ...

    Benzinga
  48. Look At That Base: If You Can't Name It, Don't Buy It

    IBD
  49. UPDATE: Goldman Sachs Downgrades Cepheid to Neutral on Lack of ...

    Benzinga
  50. Benzinga's Top Downgrades

    Benzinga
  51. Benzinga's Top Upgrades

    Benzinga
  52. CEPHEID Reports Operating Results (10-Q)

    GuruFocus
  53. UPDATE: Cantor Fitzgerald Maintains Cepheid at Hold on Analyst ...

    Benzinga
  54. UPDATE: Canaccord Genuity Reiterates Cepheid at Buy with $50 ...

    Benzinga
  55. Goldman Sachs Reiterates Buy Rating, $46 PT on Cepheid

    Benzinga
  56. UPDATE: ISI Group Reduces PT to $30.50 on Cepheid Post Analyst ...

    Benzinga
  57. Benzinga Mid-Afternoon Market Update

    Benzinga
  58. Stock Futures Point to Higher Open with Yahoo (YHOO) and Hewlett-Packard ...

    MarketIntelligenceCenter
  59. Benzinga Mid-Day Market Update

    Benzinga
  60. Mid-Morning Market Update

    Benzinga
  61. UPDATE: ISI Group Reduces PT to $32.50 on Cepheid Following Negative ...

    Benzinga
  62. Benzinga's Top Initiations

    Benzinga
  63. A Peek Into The Market Before The Trading Starts

    Benzinga
  64. UPDATE: JP Morgan Initiates Cepheid at Overweight on Growth Outlook

    Benzinga
  65. Benzinga's Top Initiations

    Benzinga
  66. Technology Sector Wrap

    FoxBusiness
  67. Technology Sector Wrap

    FoxBusiness
  68. Technology Sector Wrap

    FoxBusiness
  69. Analyst Downgrades: Cepheid, Intuitive Surgical, and Travelzoo

    SchaeffersResearch
  70. Cepheid Down 20% on Weak Guidance

    Benzinga
  71. CEPHEID (CPHD) CEO John L Bishop sells 40,201 Shares

    GuruFocus
  72. CEPHEID (CPHD) CEO John L Bishop sells 25,000 Shares

    GuruFocus
  73. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 17,437 Shares

    GuruFocus
  74. A Peek Into The Market Before The Trading Starts

    Benzinga
  75. UPDATE: UBS Investment Research Upgrades Cepheid to Buy; Opportunistic ...

    Benzinga
  76. Benzinga's Top Downgrades With Color for May 14, 2012

    Benzinga
  77. UPDATE: GARP Research & Securities Downgrades Cepheid to Neutral; ...

    Benzinga
  78. Cepheid Earnings Miss Estimates; Stock Plummets

    IBD
  79. Cepheid Q1 Estimates Soft, But Outlook For Year Good

    IBD
  80. Zoll Deal, Intutive Surgical Lift Medical Equipment

    IBD
  81. Cepheid Stock Price Rises on Strong 2012 Sales Outlook

    IBD
  82. CEPHEID Reports Operating Results (10-K)

    GuruFocus
  83. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 62,062 Shares

    GuruFocus
  84. CEPHEID (CPHD) CEO John L Bishop sells 6,887 Shares

    GuruFocus
  85. CEPHEID (CPHD) Executive VP, COO Humberto Reyes sells 133,957 ...

    GuruFocus
  86. Stocks Finish Week Split; Nasdaq, S&P 500 Higher

    IBD
  87. Stocks Stay Mixed; Under Armour Clears 50-Day

    IBD
  88. RBC Capital Upgrades Cepheid to Outperform

    Benzinga
  89. UPDATE: Credit Suisse Initiates Outperform, $40 Target on Cepheid

    Benzinga
  90. Analogic Earnings Preview: EPS Expected to Double

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!